| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.56▼ | 1.56▼ | 1.57▼ | 1.56▼ | 1.29▲ |
| MA10 | 1.57▼ | 1.56▼ | 1.53▼ | 1.48▲ | 1.33▲ |
| MA20 | 1.42▲ | 1.34▲ | 1.32▲ | 1.29▲ | 1.21▲ |
| MA50 | 1.34▲ | 1.35▲ | 1.37▲ | 1.31▲ | 1.18▲ |
| MA100 | 1.36▲ | 1.31▲ | 1.27▲ | 1.20▲ | 1.39▲ |
| MA200 | 1.24▲ | 1.20▲ | 1.19▲ | 1.15▲ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.007▲ | 0.026▲ | 0.035▲ | 0.035▲ | 0.030▲ |
| RSI | 57.223▲ | 58.166▲ | 57.602▲ | 62.006▲ | 61.382▲ |
| STOCH | 57.895 | 75.639 | 81.696▲ | 73.497 | 45.866 |
| WILL %R | -26.316 | -19.608▲ | -19.231▲ | -31.239 | -24.731▲ |
| CCI | -31.630 | 26.426 | 35.427 | 43.633 | 137.606▲ |
|
Thursday, May 01, 2025 04:25 AM
OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101) to treat NCP, an ocular condition associated with chronic ...
|
|
Wednesday, April 30, 2025 04:14 AM
LONDON and NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK ...
|
|
Wednesday, April 30, 2025 04:00 AM
Urcosimod phase 2 trial treating Neuropathic Corneal Pain (“NCP”) patients was initiated in October 2024 and designed as a double-masked, randomized, 12-week placebo-controlled trial.OKYO Pharma plans ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 02/05/25 | 1.51 | 1.51 | 1.51 | 1.51 | 6,304 |
| 01/05/25 | 1.65 | 1.65 | 1.51 | 1.565 | 296,851 |
| 30/04/25 | 1.60 | 1.65 | 1.5673 | 1.585 | 39,632 |
| 29/04/25 | 1.57 | 1.61 | 1.57 | 1.585 | 17,758 |
| 28/04/25 | 1.51 | 1.6492 | 1.5006 | 1.55 | 28,556 |
| 25/04/25 | 1.5485 | 1.5786 | 1.50 | 1.51 | 24,607 |
| 24/04/25 | 1.54 | 1.55 | 1.4738 | 1.5117 | 19,573 |
| 23/04/25 | 1.45 | 1.7099 | 1.395 | 1.50 | 228,878 |
| 22/04/25 | 1.14 | 1.39 | 1.14 | 1.34 | 59,120 |
| 21/04/25 | 1.20 | 1.20 | 1.14 | 1.17 | 12,969 |
|
|
||||
|
|
||||
|
|